<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374139</url>
  </required_header>
  <id_info>
    <org_study_id>B1871035</org_study_id>
    <nct_id>NCT01374139</nct_id>
  </id_info>
  <brief_title>Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, Single-Dose, 2-Cohort, 2-Way Crossover Bioequivalence Study To Compare The Bosutinib Clinical Tablet And Clinical Capsule And To Investigate Food Effect On Bosutinib Commercial Formulation in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the bioequivalence of the clinical tablet
      formulation (100 mg x 5) to the clinical capsule formulation (100 mg x 5) in healthy subjects
      under fed condition (Cohort 1) and to investigate the effect of a high-fat meal on the
      pharmacokinetics of bosutinib after administration of the proposed commercial tablet
      formulation (100 mg x 4) in healthy subjects (Cohort 2).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Cmax for bosutinib.</measure>
    <time_frame>96 hr post dose in each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt for bosutinib.</measure>
    <time_frame>96 hr post dose in each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma AUCinf for bosutinib.</measure>
    <time_frame>96 hr post dose in each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast for bosutinib.</measure>
    <time_frame>96 hr post dose in each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for bosutinib.</measure>
    <time_frame>96 hr post dose in each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tÂ½ for bosutinib.</measure>
    <time_frame>96 hr post dose in each period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>SKI-606, PF-05208763</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>SKI-606, PF-05208763</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female of non childbearing potential subjects between the ages of
             21 and 55 years, inclusive.

          -  Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12 Lead ECG or clinical laboratory tests.

        Exclusion Criteria:

          -  Pregnant or nursing women or women of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1871035&amp;StudyName=Bioequivalence%20And%20Food%20Effect%20Study%20Of%20Bosutinib%20In%20Healthy%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bosutinib</keyword>
  <keyword>Bioequivalence and Food Effect Studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

